Dr Reddy's Laboratories Ltd
NSE:DRREDDY

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Watchlist
Price: 1 350.9 INR 0.71%
Market Cap: 1.1T INR
Have any thoughts about
Dr Reddy's Laboratories Ltd?
Write Note

Dr Reddy's Laboratories Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dr Reddy's Laboratories Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Gross Profit
â‚ą212.7B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Gross Profit
â‚ą177.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Gross Profit
â‚ą398.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
8%
Lupin Ltd
NSE:LUPIN
Gross Profit
â‚ą147B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
6%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Gross Profit
â‚ą84.8B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
10%
M
Mankind Pharma Ltd
NSE:MANKIND
Gross Profit
â‚ą69.4B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dr Reddy's Laboratories Ltd
Glance View

Market Cap
1.1T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

DRREDDY Intrinsic Value
621.53 INR
Overvaluation 54%
Intrinsic Value
Price

See Also

What is Dr Reddy's Laboratories Ltd's Gross Profit?
Gross Profit
212.7B INR

Based on the financial report for Sep 30, 2024, Dr Reddy's Laboratories Ltd's Gross Profit amounts to 212.7B INR.

What is Dr Reddy's Laboratories Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
13%

Over the last year, the Gross Profit growth was 12%. The average annual Gross Profit growth rates for Dr Reddy's Laboratories Ltd have been 16% over the past three years , 13% over the past five years .

Back to Top